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Interleukin-8/CXCL8 (IL-8) is a chemokine and angiogenic factor. Recently, IL-8 was identified as an autocrine growth factor in several
human cancers. Here, we investigated the expression and function of IL-8 in lung cancer cells. The expressions of IL-8 and its
receptors, CXCR1 and CXCR2, were examined in a panel of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
cell lines. Using reverse transcription–polymerase chain reaction (RT–PCR) and enzyme-linked immunosorbent assay, we found that
all NSCLC cell lines tested produced modest or high levels of IL-8 (up to 51ngml
 110
6cells
 1). Expression of CXCR1 and CXCR2
was found by RT–PCR and flow cytometry in two out of three cell lines. In contrast, SCLC cell lines produced very low or
undetectable levels of IL-8, but expressed CXCR1 and CXCR2. We next investigated whether IL-8 could act as an autocrine growth
factor in two NSCLC cell lines (H460 and MOR/P) expressing both IL-8 and its receptors. We found that cell proliferation was
attenuated by anti-IL-8 neutralising antibody to 71 and 76% in H460 and MOR/P, respectively (Po0.05). Exogenous IL-8 significantly
stimulated cell proliferation in four SCLC cell lines tested in a dose-dependent fashion. Cell proliferation was increased by between
18% (Po0.05) and 37% (Po0.05). Stimulation of cell proliferation by IL-8 was also demonstrated by analysis of proliferating cell
nuclear antigen expression and cell cycle in H69 cells. Furthermore, we investigated which receptor(s) mediated the mitogenic
function of IL-8 in lung cancer cells. We found that cell proliferation was significantly reduced by anti-CXCR1 antibody but not by
anti-CXCR2 antibody. In conclusion, IL-8 can act as an autocrine and/or paracrine growth factor for lung cancer cells, and the
mitogenic function of IL-8 in lung cancer is mediated mainly by CXCR1 receptor.
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Lung cancer is the leading cause of cancer-related death in
industrialised countries. The majority of patients with lung cancer
have incurable advanced disease with very poor therapeutic
options, so new treatment approaches such as targeted therapy
are urgently needed. The malignant phenotype of lung cancer may
be partially attributable to abnormalities in growth factors and
their receptors acting via both autocrine and paracrine pathways.
An understanding of the abnormal expression of such growth
factors and their receptors is crucial to find new therapeutic
targets. Lung cancer can be classified into small cell lung cancer
(SCLC), which has a neuroendocrine phenotype, and non-small
cell lung cancer (NSCLC), which includes adenocarcinoma,
squamous cell carcinoma and large cell carcinoma. Both SCLC
and NSCLC have been shown to produce a variety of growth
factors (Woll, 1996).
Interleukin-8/CXCL8 (IL-8) is a member of the CXC chemokine
family, which was originally classified as a neutrophil chemoat-
tractant with inflammatory activity (Baggiolini et al, 1989). Two
IL-8 receptors, CXCR1 and CXCR2, have been identified. They
share 77% amino-acid identity and belong to the superfamily of
seven transmembrane domain, G protein-coupled receptors, whose
signalling is mediated by heterotrimeric G proteins, resulting in
the exchange of GDP for GTP on the a subunit of the G protein
(Wess, 1997). CXCR1 and CXCR2 have been found on many
normal cells such as neutrophils, basophils, lymphocytes, mono-
cytes, keratinocytes and endothelial cells.
Interleukin-8 is a potent angiogenic factor in several cancers
including NSCLC (Smith et al, 1994) and is associated with
metastasis (Singh et al, 1994; Ueda et al, 1994; Luca et al, 1997).
Elevated IL-8 is correlated with angiogenesis, tumour progression
and poor survival in NSCLC (Yuan et al, 2000; Masuya et al, 2001;
Orditura et al, 2002; Chen et al, 2003). CXCL8 has been shown to
be mitogenic for cancers such as melanoma (Schadendorf et al,
1993), colon cancer (Brew et al, 2000; Li et al, 2001), pancreatic
cancer (Miyamoto et al, 1998), malignant mesothelioma (Galffy
et al, 1999) and Kaposi’s sarcoma (Masood et al, 2001). However,
the role of IL-8 in lung cancer has been controversial. It was shown
that the inhibition of lung cancer growth by targeting IL-8 in a
mouse model was solely due to the inhibition of the angiogenic
effect of IL-8 (Arenberg et al, 1996). Interleukin-8 was also shown
to inhibit directly lung cancer cell proliferation in vitro (Wang et al,
1996). CXCR1 and CXCR2 were found on a variety of tumour cells,
but have not been reported in lung cancer. In this study, we
investigated the expression of IL-8 and its receptors, CXCR1 and
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sCXCR2, in a panel of NSCLC and SCLC cell lines and characterised
the mitogenic role of IL-8 in lung cancer growth.
MATERIALS AND METHODS
Lung cancer cell lines and cell culture
The SCLC cell lines used were CORL-24, GLC-19, H69, H345, H711
and Lu-165. The NSCLC cell lines used were A549, H460 and MOR/
P. All cell lines were cultured in RPMI 1640 (BioWhittaker,
Verviers, Belgium) and 10% FBS (QB perbio, Tattenhall, Cheshire,
UK) in humidified 5% CO2, 95% air at 371C. Conditioned medium
was obtained by collecting medium from MOR/P (5 10
7 cells) or
H460 (5 10
6 cells) cells cultured in 5ml of 10% FBS in RPMI 1640
for 48h.
Reverse transcription–polymerase chain reaction
The expression of mRNA for IL-8 and its receptors was determined
by reverse transcription–polymerase chain reaction (RT–PCR).
Total RNA was isolated by using the RNeasy mini kit (Qiagen,
West Sussex, UK) following the manufacturer’s protocol. A 0.5mg
portion of total RNA was reverse-transcribed for subsequent PCR
amplification for each pair of primers in a volume of 10ml,
including 10U of enhanced AMV reverse transcriptase (Sigma,
Poole, Dorset, UK), 20U of RNase inhibitor (Sigma), 0.5mgo f
oligo(dT)15 primer, 0.5nmol of each dNTP and 1  first-strand
buffer (50mM Tris-HCl, pH 8.3, 40mM KCl, 8mM MgCl2,1 m M
dithiothreitol) provided by Sigma. The reaction was incubated at
451C for 50min. A 10ml portion of the RT products was then
brought to a volume of 50ml containing 0.2nmol of each dNTP, 1U
of Taq polymerase (Sigma), 0.1mg of both the upstream and
downstream PCR primers and 1  PCR buffer (10mM Tris-HCl,
pH 8.3, 50mM KCl, 1.1mM MgCl2, 0.01% gelatin) provided by
Sigma. The primers for IL-8 are as follows: sense, 50-ATG ACT TCC
AAG CTG GCC GTG GCT-30; antisense, 50-TCT CAG CCC TCT
TCA AAA ACT TCT-30. The primers for CXCR1 are as follows:
sense, 50-CCT TCT TCC TTT TCC GCC AG-30; antisense, 50-AAG
TGT AGG AGG TAA CAC GAT G -30; The primers for CXCR2 are
as follows: sense, 50-ATT CTG GGC ATC CTT CAC AG-30;
antisense, 50-TGC ACT TAG GCA GGA GGT CT-30. The primers
for GAPDH are as follows: sense, 50-CCA CCC ATG GCA AAT TCC
ATG GCA-30; antisense, 50-TCT AGA CGG CAG GTC AGG TCC
ACC-30. Amplification was carried out in a Biometra thermal cycler
after an initial denaturation at 941C for 3min. This was followed by
35 cycles of PCR using the following temperature and time profile:
denaturation at 941C for 40s, primer annealing at 581C for
40s, primer extension at 721C for 1min and a final extension of
721C for 6min. The PCR products were visualised by electrophor-
esis on a 2% agarose gel in 0.5  TBE buffer (44.5mM Tris borate,
1m M EDTA, pH 8.3) after staining with 0.5mgml
 1 ethidium
bromide.
Enzyme-linked immunosorbent assay
The expression of IL-8 protein was determined by enzyme-linked
immunosorbent assay (ELISA). For collecting samples from
culture media, serum-free RPMI medium was used. The media
were harvested at the indicated times and stored at  201C before
analysis. The concentrations of IL-8 in the culture media were
determined by ELISA (R&D systems, Abingdon, UK) according to
the manufacturer’s instructions. Briefly, 100ml samples containing
standard amounts of recombinant IL-8 (rIL-8) or study samples
were added in triplicate to individual wells and incubated at room
temperature for 1h. After five washes, 100ml of biotinylated IL-8
antibody diluted in dilution buffer (0.1% bovine serum albumin,
0.05% Tween 20 in Tris-buffered saline (20mM Trizma-base,
150mM NaCl)) was added for 1h. After another five washes, 100ml
of streptavidin–horseradish peroxidase (HRP) conjugate that had
been diluted to 1/200 in dilution buffer was added for 30min. After
a final wash, 100ml of the substrate buffer containing the HRP
substrate tetramethylbenzidine dihydrochloride and hydrogen
peroxide in 0.05 M phosphate-citrate buffer (pH 5.0) was added
for 30min in the dark and colour developed in proportion to the
amount of IL-8 present. The reaction was stopped by adding 100ml
of stop solution (1.8 M sulphuric acid), and the degree of colour
that had been generated was determined by measuring the optical
density (OD) at 450nm in a Dynatech MR5000 microplate reader.
Flow cytometry analysis of cell surface expression of
CXCR1 and CXCR2
The cells were washed twice with phosphate-buffered saline (PBS)
and then suspended in 100ml of FACS buffer (2% bovine serum
albumin, 2% normal rabbit serum in PBS), and then 2mg of mouse
anti-human monoclonal anti-CXCR1 or anti-CXCR2 antibody or
IgG control antibody (R&D systems) was added and incubated for
40min on ice. After washing twice with PBS, the cells were
suspended in 100ml of FACS buffer plus 1:20 diluted FITC-
conjugated rabbit anti-mouse IgG (DAKO, Denmark) and
incubated for 30min on ice. The cells were washed twice with
PBS and fixed in 100ml of FACS buffer containing 1%
paraformaldehyde. The cells were analysed on a FACSort flow
cytometer (Becton Dickinson, San Jose, CA, USA).
Staining of proliferating cell nuclear antigen and DNA
The cells were suspended in 100ml of PBS and then 500ml of lysing
buffer (0.5% Triton X-100, 0.2mgml
 1 EDTA, 1% BSA in PBS) was
added for 15min on ice. The cells were fixed with 3ml of 100% ice-
cold methanol for 10min, washed once with PBS, and then 2mgo f
mouse anti-human monoclonal anti-proliferating cell nuclear
antigen (PCNA, clone PC 10, Sigma) or control mouse IgG2a
antibody (R&D systems) diluted in lysing buffer was added and
incubated for 30min at room temperature. After washing twice
with PBS, the cells were suspended in 100ml of lysing buffer plus
1:20 diluted FITC-conjugated rabbit anti-mouse IgG (DAKO,
Denmark) and incubated for 30min. The cells were washed once
with PBS and 200ml of DNA-staining solution (10mgml
 1
propidium iodide, 0.2mgml
 1 RNase, 0.1% Triton X-100 in PBS)
was added at room temperature for at least 15min. The cells were
analysed on a FACSort flow cytometer.
MTT assay
Cell proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay (Sigma, Dorset,
England). A total of 5 10
3 cells were seeded into 96-well flat-
bottomed plates in triplicate in 100ml RPMI containing 10% FCS.
After overnight culture, cells were treated with various concentra-
tions of rIL-8, monoclonal anti-IL-8, monoclonal anti-CXCR1,
monoclonal anti-CXCR2 or control antibody – mouse IgG (R&D
systems) – and conditioned medium of MOR/P and H460 for 48h.
A1 0 ml portion of MTT (5mgml
 1) was added to each well 4h
before the end of experiments. Then, MTT solvent (100ml of 0.1 N
HCl in anhydrous isopropanol) was added and absorbance of the
converted dye was measured at a wavelength of 570nm. The
background was also measured at 690nm.
Statistical analysis
All results are expressed as mean7s.d. The unpaired Student’s t-
test was used to evaluate the significance of differences between
groups, accepting Po0.05 as the level of significance.
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sRESULTS
Constitutive production of IL-8 in lung cancer cell lines
Expression of IL-8 mRNA was detected by RT–PCR, and was
found expressed in all NSCLC cell lines: A549, H460 and MOR/P.
Although IL-8 mRNA was weakly expressed in the SCLC cell lines
H69, H345 and H711, it was not expressed in Lu165, CORL24 and
GLC-19 cell lines (Figure 1A). To assess protein production, IL-8
was measured by ELISA in the supernatants of unstimulated cells
cultured in serum-free medium. No detectable IL-8 was found in
all cell lines after 6h of culture. In all three NSCLC cell lines, IL-8
was detected after 24h, H460 cells produced 6153pgml
 110
6cells
 1,
MOR/P 584pgml
 110
6cells
 1 and A549 357pgml
 110
6cells
 1.
After 48h, IL-8 levels were increased to 51282pgml
 110
6cells
 1 in
H460, 7299pgml
 110
6cells
 1 in MOR/P and 2053pgml
 110
6cells
 1
in A549. However, IL-8 secretion by SCLC cells was almost negative
at 24h and detectable in only three of six SCLC cell lines at 48h:
162pgml
 110
6cells
 1 in H69, 109pgml
 110
6cells
 1 in H345 and
100pgml
 110
6cells
 1 in H711 (Figure 1B).
Expression of CXCR1 and CXCR2 in lung cancer cells
Expression of IL-8 receptors, CXCR1 and CXCR2, was assessed by
flow cytometry and RT–PCR (Figure 2). Expression of CXCR1 and
CXCR2 protein on the cell membrane was measured by flow
cytometry (Figure 2A and B). In the SCLC cell lines, the number of
CXCR1-positive cells in Lu165 was 68%, followed by CORL24 with
45% and then the other four cell lines with between 36 and 38%. In
NSCLC cell lines, the number of CXCR1-positive cells was 35% in
H460 and 26% in MOR/P, and a few positive cells were found in
A549. In contrast to CXCR1, expression of CXCR2 was much lower
in all cell lines tested, ranging from 28% in H711 to 9% in MOR/P.
The NSCLC cell line A549 was negative for CXCR2 protein
(Figure 2C). We further compared the mRNA levels of CXCR1 and
CXCR2 in A549 and H460. CXCR1 mRNA was present in A549 but
at a lower level than in H460. CXCR2 mRNA was not present in
A549 but in H460 as expected (Figure 2D).
Interleukin-8 is an autocrine growth factor in H460 and
MOR/P cells
Although all the NSCLC cell lines produced IL-8, only two of them
(H460 and MOR/P) expressed IL-8 receptors, as there were almost
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Figure 1 Expression of IL-8 mRNA and protein in lung cancer cell lines.
Expression of IL-8 mRNA was measured by RT–PCR (A). A 1mg portion
of total RNA was reverse-transcribed for PCR reactions of IL-8 and control
GAPDH. The expected 289bp band of IL-8 mRNA was strongly expressed
in A549, H460 and MOR/P, but was undetectable in all SCLC cell lines.
Production of IL-8 protein was measured by ELISA (B). Conditioned
medium was collected after 1 10
6 cells were cultured in serum-free RPMI
medium for 48h. Each bar is the mean7s.e. of three determinations from
two independent experiments.
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Figure 2 Expression of CXCR1 and CXCR2 in lung cancer cell lines.
Expression of CXCR1 and CXCR2 proteins on the cell surface was
measured by flow cytometry with mouse anti-human CXCR1 (R1) and
CXCR2 (R2) and mouse IgG as control (C). Representative flow
cytometric histograms of A549 and Lu165 showing the low expressions
of CXCR1 and CXCR2 in A549 (A) and high expressions of CXCR1 and
CXCR2 in Lu165 (B), respectively. Percentage of positive cells of CXCR1
and CXCR2 in nine lung cancer cell lines are summarised in (C). Each bar is
the mean7s.e. of four independent experiments. Expression of CXCR1
and CXCR2 mRNA was measured by RT–PCR in A549 and H460 (as a
positive control) (D). Total RNA (1.5mg) was reverse-transcribed for PCR
reactions of CXCR1, CXCR2 and control GAPDH. The expected 512bp
band of CXCR1 was expressed in A549 and H460. The expected 202bp
band of CXCR2 was expressed in control cell H460 but not in A549 cells.
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Consistent with this, cell proliferation was enhanced by exogenous
rIL-8 in H460 and MOR/P, but not in A549 (Figure 3A). We also
tested whether expression of IL-8 receptors was associated with
cell proliferation. When NSCLC cells were 50% confluent, 36%
cells were in G1 phase and 64% cells were in S and G2/M phases. In
contrast, 67% cells were in G1 phase and 33% cells were in S and
G2/M phases when cells were 100% confluent. The number of
positive cells with CXCR1 or CXCR2 was significantly higher in
50% confluent cells than in 100% confluent cells. Positive cells with
CXCR1 and CXCR2 were increased to 43 and 28% from 22 and 6%
(both Po0.01), respectively, in H460. Positive cells with CXCR1
and CXCR2 were increased to 33 and 11% from 21 and 6% (both
Po0.01), respectively, in MOR/P (Table 1).
To test whether IL-8 acted as an autocrine growth factor in these
two cell lines, cells were cultured in the presence or absence of
anti-IL-8 antibody. Cell growth was inhibited in a dose-dependent
fashion by adding anti-IL-8 antibody. At a concentration of
10mgml
 1 of anti-IL8 antibody, cell proliferation was significantly
reduced to 71% (Po0.05) and 76% (Po0.05) in H460 and MOR/P,
respectively. In contrast, cell proliferation was not significantly
changed in A549 (Figure 3B). To determine which IL-8 receptor
mediates growth in NSCLC, we examined the effects of anti-CXCR1
and anti-CXCR2 on cell proliferation. Anti-CXCR1 antibody
significantly reduced cell proliferation of H460 (to 75%, Po0.05)
and MOR/P (to 82%, Po0.05) at a concentration of 10mgml
 1,
whereas anti-CXCR2 antibody did not significantly affect cell
proliferation of these cells (Figure 3C). A549, which lack surface
receptors, did not respond to either antibody.
Exogenous rIL-8 stimulates SCLC cell proliferation
through mainly CXCR1
Because SCLC cell lines expressed IL-8 receptors but did not
secrete IL-8, it could not act as an autocrine growth factor for these
cells. However, exogenous rIL-8 stimulated SCLC cell proliferation
in a dose-dependent fashion (Figure 4). Maximal stimulation was
obtained in three out of four tested cell lines at a concentration of
1ngml
 1. Cell growth was increased by 33% (Po0.05) in GLC-19,
31% (Po0.05) in H345 and 18% (Po0.05) in H69. Cell
proliferation of Lu165 was increased to 37% (Po0.05) with rIL-8
at 10ngml
 1 (Figure 4A). To support this result, expression of
PCNA, a marker for proliferating cells, and cell cycle were analysed
in H69 cells. After IL-8 stimulation (1ngml
 1), the mean
fluorescent intensity (MFI) of PCNA was increased to 65 from 35
in H69 (Figure 4B); the G1 phase was decreased to 29% from 43%,
and S and G2/M phases were increased to 41 and 30% from 38 and
19%, respectively (Figure 4C). To determine which IL-8 receptor
was involved in IL-8 stimulation, cells were treated with either
anti-CXCR1 (10mgml
 1) or anti-CXCR2 (10mgml
 1) and rIL-8 for
48h. Anti-CXCR1 antibody significantly reduced the proliferation
stimulated by IL-8 in all SCLC cell lines (Po0.05). However, anti-
CXCR2 antibody did not significantly reduce the proliferation
(Figure 4D), indicating that the mitogenic effects of IL-8 in SCLC
are mainly mediated by the CXCR1 receptor.
DISCUSSION
Interleukin-8 has been shown to be an important mitogenic factor
in a variety of cancers including melanoma (Schadendorf et al,
1993; Singh et al, 1994), colon cancer (Brew et al, 2000; Li et al,
2001), pancreatic cancer (Miyamoto et al, 1998), malignant
mesothelioma (Galffy et al, 1999) and Kaposi’s sarcoma (Masood
et al, 2001). The role of IL-8 in lung cancer has not been fully
defined. Although there are several reports on lung cancer-derived
IL-8 and its effect on tumour growth, their results remain
controversial and unclear. Wang et al (1996) reported that
exogenous rIL-8 and cancer-derived IL-8 inhibited lung tumour
proliferation by both autocrine and paracrine pathways in A549
and four other lung cancer cell lines. However, Arenberg et al
reported that tumour-derived IL-8 directly correlated with the rate
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Figure 3 Interleukin-8 is an autocrine growth factor in H460 and MOR/P
cells. (A) Non-small cell lung cancer cells were treated with rIL-8 (at a
concentration of 0, 1, 10 and 100ngml
 1) for 48h. Cell proliferation was
measured by MTT assay. Each point is the mean7s.e. of three
determinations from two independent experiments. (B) Non-small cell
lung cancer cells were treated with anti-IL-8 neutralising antibody (1 or
10mgml
 1) for 48h. Cell proliferation was measured by MTT assay. Each
bar is the mean7s.e. of three determinations from two independent
experiments. *Po0.05. (C) Non-small cell lung cancer cells were treated
with anti-CXCR1 or anti-CXCR2 neutralising antibody (10mgml
 1)o r
control antibody (mouse IgG at 10mgml
 1) for 48h. Cell proliferation was
measured by MTT assay. Each bar is the mean7s.e. of three determina-
tions from two independent experiments. *Po0.05.
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sof growth of the two human NSCLC cells lines A549 and Calu-1 in
SCID mice. Interleukin-8 promoted human lung cancer growth
through its angiogenic properties. Interleukin-8 was not found to
behave as an autocrine growth factor for the proliferation of
NSCLC cells (Arenberg et al, 1996). The expression of CXCR1 and
CXCR2 was not investigated in these reports. The present study
has investigated the expression of both IL-8 and its receptors
simultaneously for the first time in a panel of lung cancer cell lines.
We found that NSCLC cells produced significant amounts of IL-8.
However, SCLC cells produced low or undetectable levels of
IL-8. These results were in agreement with previous studies.
Many NSCLC cells including A549 and H460 were shown to
produce IL-8 (Arenberg et al, 1996; Yatsunami et al, 1997;
Anderson et al, 2000; Chen et al, 2003) and SCLC cells including
H345 were shown to produce low or undetectable levels of IL-8
(Yatsunami et al, 1997).
Since the expression of CXCR1 and CXCR2 has not been studied
in lung cancer cells, we next examined the expression of these
receptors on cell surface by flow cytometry. In NSCLC cells,
CXCR1 and CXCR2 were found on H460 and MOR/P, but very few
CXCR1 and no CXCR2 were found on A549. By RT–PCR, A549
expressed CXCR1 mRNA but not CXCR2 mRNA. In SCLC cells,
CXCR1 and CXCR2 were expressed in all cell lines. SCLC cells
responded to exogenous rIL-8 in a dose-dependent fashion. Cell
proliferation reached a peak at an rIL-8 concentration of 1ngml
 1
in most cell lines, but cell proliferation reached a peak at an rIL-8
concentration of 10ngml
 1 in Lu165. This may reflect the fact that
Lu165 cell expressed more receptors, especially CXCR1, than other
cells. These results indicated that IL-8 could act as a paracrine
growth factor in SCLC cells.
The finding that IL-8 and its receptors are coexpressed in H460
and MOR/P cell lines led us to speculate that IL-8 could act as an
Table 1 Correlation of expression of CXCR1 and CXCR2 with cell proliferation
H460 MOR/P
100% confluency 50% confluency 100% confluency 50% confluency
CXCR1 (%) 22.671.7 43.573.3
* 21.071.6 33.071.7
*
CXCR2 (%) 6.170.5 28.272.4
* 6.270.4 11.070.6
*
*Po0.01.
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Figure 4 Recombinant IL-8 stimulates SCLC cell proliferation through CXCR1. (A) The SCLC cell lines H69, Lu165, H345 and GLC-19 were treated
with rIL-8 at concentrations of 0.01, 0.1, 1 and 10ngml
 1 for 48h. Cell proliferation was measured by MTT assay. Each point is the mean7s.e. of three
determinations from two independent experiments. *Po0.05. (B) Detection of PCNA intensity by flow cytometry after H69 cells was treated with rIL-8
(1ngml
 1) for 48h. (C) Analysis of DNA content by flow cytometry after H69 cells was treated with rIL-8 (1ngml
 1). (D) Small cell lung cancer cells were
treated with rIL-8 plus anti-CXCR1 or anti-CXCR2 antibody for 48h. The concentration of rIL-8 for each cell line was chosen for maximal stimulation:
10ngml
 1 for Lu165 and 1ngml
 1 for others. The final concentration of anti-CXCR1 or anti-CXCR2 was 10mgml
 1. Each bar is the mean7s.e. of three
independent determinations of two experiments. *Po0.05 for inhibition of rIL-8-induced proliferation by anti-CXCR1 antibody.
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growth was stimulated by exogenous rIL-8 in H460 and MOR/P,
but not in A549. Also, cell growth was significantly inhibited in a
dose-dependent fashion by adding anti-IL-8 neutralising antibody
to 71 and 76% in H460 and MOR/P, respectively. In contrast, cell
proliferation was only slightly decreased in A549. These results
suggest that IL-8 is an autocrine growth factor in H460 and MOR/
P, but not in A549 NSCLC cells because they lack receptors. This
may explain why IL-8 was not found to act as an autocrine growth
factor in A549 cells in a previous study (Arenberg et al, 1996).
We further investigated which IL-8 receptor(s) mediated the
mitogenic function of IL-8 in lung cancer cells. The biological
activity of IL-8 is mediated by binding to two closely related
receptors, CXCR1 and CXCR2. CXCR1 binds only IL-8 and CXCL6
(granulocyte chemotactic protein-2, GCP-2), but CXCR2 binds all
known angiogenic CXC chemokines that contain the Glu-Leu-Arg
(ELR) motif including IL-8 (Lee et al, 1992). Our results showed
that all the lung cancer cell lines tested expressed CXCR1 and
CXCR2 except A549. In these cell lines, expression of CXCR2
protein was much weaker than CXCR1. The role of each of these
receptors in IL-8-mediated activity remains controversial. Previous
studies have shown that the angiogenic effects of IL-8 in human
microvascular endothelial cells and NSCLC were mediated by
CXCR2 (Addison et al, 2000; Salcedo et al, 2000; Heidemann et al,
2003). The chemotactic response of melanoma cells to IL-8 was
mediated by CXCR1 (Ramjeesingh et al, 2003), and the mitogenic
activity of IL-8 was mediated by both CXCR1 and CXCR2 in colon
cancer (Li et al, 2001), but only by CXCR1 in monocytes
(Browning et al, 2000). Our results show that CXCR1 is the major
receptor that mediates the mitogenic function of IL-8 in lung
cancer. Also, there was evidence of crosstalk between the IL-8 and
epidermal growth factor (EGF) receptors. Venkatakrishnan et al
(2000) reported that in ovarian cancer cells the signal through
CXCR1 and CXCR2 by IL-8 transactivated EGF receptor, which is
an effective therapeutic target of many EGF receptor inhibitors in
NSCLC. Overall, we have shown that IL-8 can function as an
autocrine and/or paracrine growth factor in lung cancer cells.
Therefore, targeting both IL-8 production and CXCR1 expression
may contribute to control of lung cancer progression, invasion and
metastasis through both angiogenic and mitogenic properties of
IL-8.
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